Barry J D, Koch T J, Cohen C, Brigati D J, Sharkey F E
Am J Clin Pathol. 1984 Nov;82(5):582-5. doi: 10.1093/ajcp/82.5.582.
In a series of 46 cases of primary mammary ductal carcinoma, immunohistochemical markers of differentiation (casein, human placental lactogen, alphalactalbumin, pregnancy specific beta-1 glycoprotein, secretory component, CEA, and peanut lectin agglutinins [PLA]), were quantitated via point-counting. An immunoperoxidase bridge (PAP) was used to identify all except the PLA, in which an avidin-biotin complex with alkaline phosphatase development was employed. For none of the markers was there any difference in the quantity present in tumors of patients who had recurred versus the tumors of patients who had enjoyed a minimum of five years disease-free survival. Nonneoplastic epithelium was only rarely positive for these markers. Although eventually surmounted, technical problems significantly hampered application of morphometry to this histochemical material. The authors conclude that these markers have little relationship to differentiation toward mammary duct epithelium and that they do not provide significant prognostic information in patients with breast cancer.
在46例原发性乳腺导管癌病例中,通过点计数法对分化免疫组化标志物(酪蛋白、人胎盘催乳素、α-乳白蛋白、妊娠特异性β-1糖蛋白、分泌成分、癌胚抗原和花生凝集素[PLA])进行定量分析。除PLA外,采用免疫过氧化物酶桥(PAP)法识别所有标志物,对于PLA则采用结合碱性磷酸酶显色的抗生物素蛋白-生物素复合物法。对于所有标志物而言,复发患者肿瘤中标志物的含量与至少有五年无病生存期患者肿瘤中的标志物含量均无差异。非肿瘤性上皮细胞仅极少情况下对这些标志物呈阳性反应。尽管最终得以克服,但技术问题严重阻碍了形态计量学在这种组织化学材料中的应用。作者得出结论,这些标志物与乳腺导管上皮分化关系不大,并且它们不能为乳腺癌患者提供重要的预后信息。